IL115582A0 - Methods for treating resistant tumors - Google Patents

Methods for treating resistant tumors

Info

Publication number
IL115582A0
IL115582A0 IL11558295A IL11558295A IL115582A0 IL 115582 A0 IL115582 A0 IL 115582A0 IL 11558295 A IL11558295 A IL 11558295A IL 11558295 A IL11558295 A IL 11558295A IL 115582 A0 IL115582 A0 IL 115582A0
Authority
IL
Israel
Prior art keywords
methods
resistant tumors
treating resistant
treating
tumors
Prior art date
Application number
IL11558295A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL115582A0 publication Critical patent/IL115582A0/xx
Priority to IL12948099A priority Critical patent/IL129480A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL11558295A 1994-10-14 1995-10-12 Methods for treating resistant tumors IL115582A0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL12948099A IL129480A0 (en) 1994-10-14 1999-04-15 Some benzothiophenes for use in treating tachykinin-dependent disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32317694A 1994-10-14 1994-10-14

Publications (1)

Publication Number Publication Date
IL115582A0 true IL115582A0 (en) 1996-01-19

Family

ID=23258042

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11558295A IL115582A0 (en) 1994-10-14 1995-10-12 Methods for treating resistant tumors

Country Status (14)

Country Link
US (2) US6124311A (fr)
EP (2) EP0709090A3 (fr)
JP (1) JPH10512544A (fr)
CN (1) CN1168631A (fr)
AU (1) AU702301B2 (fr)
CA (1) CA2202661A1 (fr)
CZ (1) CZ113797A3 (fr)
FI (1) FI971568A7 (fr)
HU (1) HUT77604A (fr)
IL (1) IL115582A0 (fr)
MX (1) MX9702700A (fr)
NO (1) NO971704L (fr)
WO (1) WO1996011677A1 (fr)
ZA (1) ZA958688B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA961564B (en) * 1995-02-28 1997-08-27 Lilly Co Eli Methods of inhibiting ovarian cancer.
EP0729754A2 (fr) * 1995-02-28 1996-09-04 Eli Lilly And Company 2-Phényl-3-aroylbenzothiophènes pour inhiber les tumeurs estrogène-positives du cerveau ou du SNC
EP0773217A1 (fr) * 1995-11-07 1997-05-14 Eli Lilly And Company Dérivés de benzothiophènes pour le traitement de tumeurs résistantes
CA2206752A1 (fr) 1996-07-02 1998-01-02 George Joseph Cullinan Composes de benzothiophene,intermediaires, procedes et methodes d'utilisation
CA2214922A1 (fr) * 1996-09-27 1998-03-27 Eli Lilly And Company Composes de benzothiofene, compositions et methodes
BR9713661A (pt) * 1996-12-30 2000-10-24 Battelle Memorial Institute Formulação e método para o tratamento de neoplasmas por inalação
ATE286395T1 (de) 1997-04-30 2005-01-15 Lilly Co Eli Antithrombotische mittel
EP0973517A4 (fr) 1997-04-30 2002-07-24 Lilly Co Eli Agents antithrombotiques
WO1998049160A1 (fr) 1997-04-30 1998-11-05 Eli Lilly And Company Agents antithrombotiques
CA2287993A1 (fr) 1997-04-30 1998-11-05 Mary George Johnson Agents antithrombotiques
US5840721A (en) * 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators
US6284756B1 (en) 1998-04-30 2001-09-04 Eli Lilly And Company Antithrombotic agents
CA2346029A1 (fr) * 1998-10-02 2000-04-13 Anthony R. Imondi Chimiotherapie par inhalation pour la prevention et le traitement des tumeurs metastatiques du poumon
DK0997460T3 (da) * 1998-10-28 2003-03-31 Lilly Co Eli Benzothiophenforbindelser som antithrombotiske midler og mellemprodukter
WO2000048541A1 (fr) * 1999-02-19 2000-08-24 Brooks Norman A Chlorure de zinc utilise dans le traitement de maladies de la peau
WO2002020478A1 (fr) * 2000-08-24 2002-03-14 Dublin City University Derives d'acide acetique n-benzylindole-3 pouvant etre utilises dans le traitement de cancers pharmacoresistants
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US7425565B2 (en) * 2002-05-09 2008-09-16 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
US6630454B2 (en) * 2001-09-10 2003-10-07 Ramot At Tel-Aviv University Ltd. Method and pharmaceutical composition for the treatment of cancer
US20040167139A1 (en) * 2002-07-26 2004-08-26 Potter David A. Methods of treating cancer
CN1281210C (zh) * 2003-11-29 2006-10-25 胡汛 五味子乙素在制备治疗肿瘤药物中的应用
US7868037B2 (en) * 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) * 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) * 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1771169A1 (fr) * 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Procedes pour le traitement de l'hepatite c
JP2008507518A (ja) * 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するためのチエノピリジン
FR2873692B1 (fr) * 2004-07-29 2006-12-01 Univ Claude Bernard Lyon COMPOSITIONS CONTENANT, EN ASSOCIATION AVEC UN AGENT ANTIMICROBIEN, UN COMPOSE THIOPHENIQUE OU BENZOTHIOPHENIQUE DE FORMULE(I)PRESENTANT UNE ACTIVITE INHIBITRICE DE POMPE NorA
FR2913017A1 (fr) * 2007-02-23 2008-08-29 Cerep Sa Derives de piperidine et piperazine comme agents anti-neoplasiques ou inhibiteurs de proliferation cellulaire
CN117865872A (zh) * 2014-12-18 2024-04-12 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
CN107406424B (zh) * 2014-12-18 2020-08-25 豪夫迈·罗氏有限公司 雌激素受体调节剂及其用途
CN108129375B (zh) * 2018-01-30 2020-04-28 中山大学 化合物及其制备方法与在制备肿瘤耐药逆转剂中的应用
CN117603219B (zh) * 2023-11-29 2025-08-08 浙江大学 一种p-糖蛋白抑制剂及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4230862A (en) 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
CA2118096A1 (fr) * 1993-10-15 1995-04-16 Srinivasan Chandrasekhar Nouveaux derives d'arylglycinamide, procedes pour les fabriquer et compositions pharmaceutiques contenant ces composes
JPH09507071A (ja) * 1993-12-21 1997-07-15 イーライ・リリー・アンド・カンパニー アミロイド原性ペプチドに関連した状態を治療又は予防する方法
WO1995017382A1 (fr) * 1993-12-21 1995-06-29 Eli Lilly And Company Antagonistes non peptidiques des recepteurs des tachykinines
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy

Also Published As

Publication number Publication date
US6124311A (en) 2000-09-26
FI971568L (fi) 1997-06-12
JPH10512544A (ja) 1998-12-02
US6121292A (en) 2000-09-19
CN1168631A (zh) 1997-12-24
EP0820769A3 (fr) 1998-08-19
NO971704L (no) 1997-05-13
EP0709090A2 (fr) 1996-05-01
FI971568A7 (fi) 1997-06-12
CZ113797A3 (en) 1997-09-17
AU702301B2 (en) 1999-02-18
NO971704D0 (no) 1997-04-14
EP0709090A3 (fr) 1996-08-28
CA2202661A1 (fr) 1996-04-25
WO1996011677A1 (fr) 1996-04-25
MX9702700A (es) 1997-06-28
AU3829895A (en) 1996-05-06
EP0820769A2 (fr) 1998-01-28
HUT77604A (hu) 1998-06-29
FI971568A0 (fi) 1997-04-14
ZA958688B (en) 1997-04-14

Similar Documents

Publication Publication Date Title
ZA958688B (en) Methods for treating resistant tumors
GB2288123B (en) Tumor treatment apparatus
GB9509091D0 (en) Quick-set formation treating methods
AP2002002661A0 (en) Combination therapy for oesteoporosis
GB9411080D0 (en) Treatment
IL122718A0 (en) Methods for treating diabetes
ZA953078B (en) Effective therapy for epilepsies
AU125475S (en) Apparatus for treating food
GB9824530D0 (en) Collimnator for radiotherapy apparatus
ZA9533B (en) Pentolifylline therapy
GB9422172D0 (en) Security apparatus
GB2286630B (en) Security apparatus
AU3543495A (en) Methods for identifying and treating resistant tumors
GB2302308B (en) Anti counterfeit apparatus
AU7602896A (en) Methods for treating resistant tumors
GB2287059B (en) Security Apparatus
CZ71095A3 (en) Track ballastway treating machine
IL126657A0 (en) Method for treating or preventing ischemia-reperfusion injury
ZA971899B (en) Method for treating insomnia
PL320564A1 (en) Therapeutic set for treating osteoporosis
GB9517701D0 (en) Method for treating hyperlipidemia
HU9400631D0 (en) Process for treating tumors
CZ72895A3 (en) Track ballastway treating machine
IL126160A0 (en) Method for treating insomnia
GB9625656D0 (en) Infrared-transmitted apparatus